Alpha Haemolysin Detection for VAP Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for predicting the progression of ventilator-associated pneumonia (VAP) in asymptomatic subjects heavily colonized with methicillin-susceptible Staphylococcus aureus (MSSA), leading to delayed antibiotic therapy and increased morbidity and mortality.
Innovation Solution
Determining the alpha haemolysin level in biological samples of ventilated subjects colonized with MSSA, where elevated levels indicate a risk of VAP onset, using a method that compares the alpha haemolysin level to a predetermined reference value, and employing a diagnostic kit with specific detection molecules for alpha haemolysin to assess disease risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antibiotics are used to treat S. aureus infections, then infection treatment is achieved, but multi-drug resistant strains emerge
Solution Approach 1:
The patent performs serial microbial analysis of endotracheal aspirates to detect S. aureus colonization and quantify bacterial load before clinical symptoms of VAP appear. This preliminary detection enables early intervention with targeted antibiotics, preventing the need for broad-spectrum antibiotic use and thereby reducing the selection pressure that drives multi-drug resistance development
Solution Approach 2:
The patent implements continuous monitoring of bacterial colonization status through serial microbial analysis, providing feedback on the effectiveness of treatment and the development of resistance. This feedback loop allows for adjustment of antibiotic therapy to maintain effectiveness while minimizing resistance development
2Loss of time
If serial microbial analysis is performed to identify and quantify bacteria, then early detection of colonization is achieved, but healthcare costs and resource utilization increase
Solution Approach 1:
The patent applies semi-quantitative evaluation specifically to endotracheal aspirate samples from high-risk ventilated patients, focusing resources on the most critical population. By concentrating diagnostic efforts on patients with the highest probability of VAP development, the system achieves early detection without universally applying costly serial microbial analysis to all patients
Solution Approach 2:
The patent uses semi-quantitative evaluation to categorize bacterial load into discrete levels (>+++ or 3+ growth), transforming continuous bacterial concentration data into actionable categories. This parameter transformation enables efficient clinical decision-making with simplified results that reduce interpretation time and resource requirements compared to full quantitative analysis
3Ease of operation
If antibiotic therapy is delayed until symptom onset, then treatment simplicity is maintained, but patient morbidity and mortality increase
Solution Approach 1:
The patent detects S. aureus colonization and quantifies bacterial load before clinical symptoms of VAP appear, enabling preliminary identification of at-risk patients. This early detection allows clinicians to initiate targeted antibiotic therapy prophylactically or at the very onset of disease, improving patient outcomes without significantly complicating the treatment workflow
Solution Approach 2:
The patent introduces serial microbial analysis of endotracheal aspirates as an intermediary diagnostic step between patient admission/ventilation and clinical VAP diagnosis. This intermediary test provides early warning of impending VAP, allowing timely intervention that bridges the gap between simple monitoring and complex diagnostic workups
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for early identification of subjects at risk for VAP, enabling timely antibiotic therapy and potentially reducing ICU stay and healthcare costs by predicting disease progression before symptom onset.
Implementation Method 1
The detection molecule is an alpha haemolysin binder selected from the group consisting of an antibody, antibody fragment, cellular receptor or ligand
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The invention relates to a method for the prediction of S. aureus disease in a subject heavily colonized by S. aureus but not showing any symptom of S. aureus disease, said method comprising the step of determining the alpha haemolysin level in a biological sample of said subject as compared to a standard or reference control, wherein an elevated alpha haemolysin level or activity is indicative of the onset of S. aureus disease.